Patent ID: 9394353
Filing Date: 2016-07-19
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method for improving the bioavailability of a Factor VIII molecule after non-intravenous administration, comprising non-intravenously administering a modified Factor VIII molecule to a subject at a reduced dosage, wherein the modified Factor VIII molecule comprises a Factor VIII molecule modified by inactivating the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, and wherein the modified Factor VIII molecule is non-intravenously administered at a dosage of 20 IU/kg to 50 IU/kg, while at least maintaining or improving the bioavailability as compared to (A) a higher dosage of a non-intravenously administered human wild type Factor VIII molecule, and/or (B) a higher dosage of a non-intravenously administered B-domain deleted human Factor VIII molecule in which Asn745 is fused to Pro1640, and wherein the non-intravenous administration is chosen from subcutaneous, intramuscular, intraperitoneal, intradermal, and transdermal administration.